NWBO Northwest Biotherapeutics Inc

$NWBO Know what you hold and what they need you to sell to them to survive. In the published Phase III data, DCVax-L was associated with a 17% longer median overall survival, while subsequent patient-level BNOS analyses suggest the survival advantage may be closer to roughly 20–38% or more. Most strikingly, 5-year survival was 13.0% with DCVax-L versus 5.7% in the control population—a 128% relative increase in the proportion reaching five years. Fuck the fud.

$NWBO Nice try to all the bashers I’m buying a lot more when you bring it down. Hope every supporter for NWBO does the same. Do not let them get your shares, get theirs, they need a lot to fulfill their naked short positions

$NWBO Hopefully NWBO releases an 8-K tomorrow related to the presentation. That and MHRA gets off their rears and grant approval.

$NWBO Does anyone else feel like there’s a lot going on behind the scenes that we don’t know about.

$NWBO So citidel and virtu don’t want us to see the response from nwbo. Then it must be one HELLUVA response. Now i wanna 👀👀👀

$NWBO The Next Bridge/McCabe story shows how dangerous market-structure disputes can become, but NWBO has an important difference: naked shorting and spoofing aren’t the same. Naked shorting can be extremely difficult to prove, while alleged spoofing potentially leaves a digital trail—orders, timestamps, modifications, cancellations and executions. NWBO chose that federal litigation route, survived major dismissal challenges and is now deep in discovery. Meanwhile, NWBO isn’t depending on the lawsuit alone: MHRA’s DCVax-L review, DCVax/Keytruda research and other corporate developments remain potential catalysts. And don’t forget the Saudi non-binding MOU—if that relationship ultimately produces a binding agreement, that could become another significant development. Multiple independent fronts are moving; any material positive news could change how the market evaluates $NWBO.

$NWBO 🚨 This just got VERY interesting for $NWBO. Dr. Mehmet Oz, CMS Administrator, publicly discussed the extraordinary case of an 18-year-old Stage IV glioblastoma patient who reportedly achieved NED after receiving DCVax-L — and said he intends to investigate the case. This isn’t just another investor post. A senior U.S. health official says the case has reached him directly from the President. If the medical records confirm the story, the potential implications are significant: national media attention, independent medical scrutiny, and potentially much broader awareness of DCVax-L. We know that this is far from an isolated case. Dr. Oz will discover that and will open the door to a much bigger investigation. The spotlight is now getting very bright. 🔦 $NWBO $DCVAX Diamonds 💎 🙌 HODL MOASS100

$NWBO The entire toxicity profile for DCVax‑L in the Phase III trial it’s nothing compared to the brutal, body‑breaking toxicity of chemo, radiation, or checkpoint inhibitors. SO WHY THE FK ISNT IT APPROVED YET !! ⭐ DCVax‑L Toxicities (Documented in the Trial) Injection‑site reactions Mild redness Mild swelling Mild soreness These are the same things you get from a tetanus shot or a flu shot. Not dangerous. Flu‑like symptoms Low‑grade fever Fatigue Chills These are normal immune activation signs. Temporary. Headache Mild to moderate Short duration Managed with Tylenol or ibuprofen Not dangerous. Serious adverse events Extremely rare Around 0.5% of patients No organ failure No immune collapse No treatment‑related deaths This is unheard of in oncology. ⭐ Now compare that to chemo, radiation, and Keytruda Chemo Organ damage Bone marrow collapse Severe infections Heart failure Kidney failure Secondary cancers Death from toxicity Radiation Brain necrosis Cognitive decline Organ damage Permanent tissue injury Secondary tumors Fatal complications Keytruda / Opdivo Pneumonitis Colitis Hepatitis Myocarditis Endocrine failure Neurological toxicity Multi‑organ inflammation Fatal immune reactions 4+ pages of toxicities in the prescribing info ⭐ The heart of the whole DCVax‑L debate “These are nothing compared to chemo, radiation, and Keytruda!” DCVax‑L doesn’t: poison the body destroy organs collapse the immune system cause multi‑organ inflammation kill the patient before the cancer does It’s one of the few cancer therapies where: the immune system is trained, not hijacked the body is supported, not attacked the treatment doesn’t become the enemy the toxicity profile is humane the benefit is meaningful

$NWBO I F$CKING HATE how the media and news is paid to push agendas, and I hate that a healthier, safer alternative to one of the largest illnesses isn’t bigger news! I know when I stand before God, I have lived a life of honestly and integrity (minus 4 years at PSU alum 🤣). I know others opposing DCVAX will pay for their greedy sins!!!!!!! As a father of two girls, 9 & 11, my blood boils knowing who opposes us for $$$$ but my heart is happy one mother will not see her daughter pass before she does!!!

$NWBO — I'M DONE WITH THE HOPIUM. I'm not going to keep finding excuses for management or pretending every little development is some massive catalyst. 1,013 days. $0.1546 close. Continued dilution. Financial pressure. Still no MHRA decision. I'm pissed off. Management owes shareholders better communication, and after this length of time, I think it's completely fair to question the MHRA process too. Enough speculation. Enough waiting. Give us the decision.

$NWBO MHRA made updates to the commercial MIA on sep. 7th, but they also updated the investigational manufacturing on sept. 15th, which i havent seen talked about yet. The two together shows progress on the MHRA side, but we dont know what that progress was. Regardless, its a move in the right direction, so hopefully that ends up being good news for us soon!

$NWBO Keep in mind we are up against monsters. Donald Trumps company was heavily naked shorted as was Elons Tesla and they were powerless. We do have one advantage over those companies and that’s the court of public appeal. When the world finds out what these monsters are doing here there should be public outrage. Now the challenge is to get the word out by any means possible. Yes it’s going to take some time. This is world changing science, cancer has finally met its match. You have your assignment. Go

$NWBO big Friday this week!!! Lets GO! ATL-DC/keytruda results are coming out! Will post link in comments!

$NWBO The setup is getting increasingly interesting. NWBO is expanding manufacturing capacity, preparing U.S./UK production, and has an MOU with Saudi partners covering commercialization and potential localized DCVax-L manufacturing. Meanwhile, MHRA has confirmed the DCVax-L application remains under review and is progressing toward a first regulatory decision. None of this guarantees approval, but you have to ask: would NWBO be making these moves if management didn't see a realistic path to commercialization? The MHRA decision remains the major catalyst. 👀 $NWBO $GBM.X $MRK

$NWBO I had Gemini analyze these three documents. So far these results look good for us! Essentially NWBO created a moat with DCVAX-L, and interested companies will be paying a premium. At least that is what it's telling me.

$NWBO Lorraine Morris · 11m Thanks to - I note that Citadel & Virtu just asked a New York judge to keep the public from seeing how their systems actually handle orders in Northwest Biotherapeutics. 🔹NWBO is ticker for Northwest Biotherapeutics, Inc., a small Bethesda-based biotech developing DCVax, a personalized dendritic-cell vaccine aimed at solid tumors, with its lead program in glioblastoma. 🔹The company has spent years alleging that market makers used spoofing & related tactics to suppress its share price while it tried to fund that work. 🔹The case, Northwest Biotherapeutics, Inc. v. Citadel Securities LLC, is now in discovery in the Southern District of New York. 🔹On 21 September 2026 the defendants filed a letter (ECF 350) asking Magistrate Judge Gary Stein to seal portions of NWBO’s 16 September response & Appendix A. 🔹They are not asking to hide the entire filing. They want the excerpts of internal trading data & the quotations from their own sealed declarations kept off the public docket. 🔹Those materials, they say, come from systems they marked “Highly Confidential.” 🔹The data show how their engines process, route and execute OTC trades in NWBO. 🔹The declarations (Dan Yara for Citadel, Robert Verderese for Virtu) describe the inner workings of those proprietary platforms. 🔹Defendants argue that technical detail has no legitimate public interest & that courts in this district routinely protect it. 🔹I beg to differ. 🔹The court has already sealed similar OTC Markets data earlier in the case. 🔹NWBO itself takes no position on whether the new material should stay sealed. 🔹That is the official record. 🔹Logically, if two of the largest market makers in the world fight this hard to keep even redacted summaries of how their machines treat one small-cap cancer-vaccine company out of public view, it is reasonable to ask what the same machines do when no U.S. lawsuit is watching? 🔹Well - Virtu’s European hub sits in Dublin. 🔹Virtu Financial Ireland Limited is authorised MiFID firm that passports across the European Union. 🔹Under MiFIR it must send transaction reports to the CBI &, where relevant, to other national competent authorities. 🔹Those reports are supposed to include cancellations and amendments, properly flagged, so supervisors can reconstruct order books & detect layering or spoofing. 🔹The U.S. filing of course does not prove that reporting is incomplete in Ireland. 🔹But it does show that Virtu treats the mechanics of its OTC order handling as a “crown jewel” that must stay hidden - even from a federal court record. 🔹When a firm fights that hard to keep the plumbing secret in one jurisdiction, people who follow both the NWBO lawsuit & European market-structure rules start asking the same question: 🔹What would a full, unredacted look at cancel & amend reporting from the Irish entity actually reveal? 🔹That is the shudder. Not a courtroom finding. 🔹Just the logical next thought after reading a letter that treats ordinary trading-system descriptions as too dangerous for daylight; especially when the stock in question belongs to a company trying to bring a brain-cancer vaccine to patients; 🔹If the Central Bank of Ireland applies a light touch to American market-making affiliates the way parts of the funds world have long treated Dublin as a convenient, lightly supervised on-ramp - Ireland for Law (wink wink) - then the surveillance net that is supposed to catch abusive cancels & amends is thinner than the rulebook suggests. 🔹Price discovery in names that live on thin OTC books can stay distorted for longer, retail and long-only holders eat the slippage & the cost of capital for companies trying to fund real work stays higher than it should. 🔹Investors who cannot see the order flow & cannot trust that the home regulator is demanding a complete picture of every cancel and amend are sadly “flying without instruments”.

$NWBO short interest (legal) grew 5m+ in two weeks. I’ve never seen it this high. Who is shorting and what lengths will they go to keep it down?

$NWBO BP just had to say mrna works and it goes from $50 to $175 and here we are at less than .17 and works better.

$NWBO Very nice find! I find this particularly noteworthy: "While standard of care yields a 5.7% five-year survival rate, the rate for those treated with ATL-DC rises to 13%. In the subset of patients whose tumor exhibit hypermethylation of the MGMT gene, the fraction of patients surviving past 5-year mark nearly doubles to 25%, with their median survival extended from 21 to 33 months after ATLDC therapy." All based on an NCI grant. Hmmmm...

$NWBO https://www.reuters.com/legal/litigation/merck-daiichi-sankyo-withdraw-us-application-lung-cancer-drug-2026-09-25/ Merck Daiichi partnership pulled their second ADC cancer drug. Bodes well towards NWBO Merck partnership as the combo DcVaxL+Keytruda to treat rGBM is a huge breakthrough.